华仁药业：公司通过企业内生增长和外延并购推动主营业务快速稳定发展

Group 1 - The company emphasizes that its stock price is influenced by multiple factors and it takes stock performance seriously [1] - The company is driving rapid and stable development of its main business through internal growth and external mergers and acquisitions [1] - The company's operating conditions for 2025 will be disclosed in the annual report for that year [1]